Literature DB >> 8700168

The stoichiometry and affinity of the interaction of murine Fc fragments with the MHC class I-related receptor, FcRn.

S Popov1, J G Hubbard, J Kim, B Ober, V Ghetie, E S Ward.   

Abstract

The binding of recombinant wild type and mutant Fc-hinge fragments to soluble, FcRn expressed in insect cells has been analysed. The mutant Fc-hinge fragments are derived from murine IgG1 with mutation of residues located at the CH2-CH3 domain interface (Ile253, His31O, Gln311, His433 and Asn434; EU numbering). These mutant Fc-hinge fragments have previously been shown to be deficient in neonatal transcytosis in suckling mice and also have abnormally short serum half lives. The mutated residues are highly conserved in human and rodent gammaglobulins (IgGs) and are also involved in binding to staphylococcal protein A. This study demonstrates that the Fc mutants have lower binding affinities for recombinant FcRn and mutations in the CH2 domain have a greater effect than those in the CH3 domain. There is an excellent correlation between affinity and transcytosis or the control of catabolism, and this provides further evidence in support of the close overlap of the sites of IgG/Fc involved in these processes. The stoichiometry of the FcRn:Fc interaction has also been investigated and has been found to be 1:1, indicating that binding of FcRn to one CH2-CH3 domain interface site precludes an FcRn:Fc interaction at the second site.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700168     DOI: 10.1016/0161-5890(96)00004-1

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  36 in total

Review 1.  Transcytosis and catabolism of antibody.

Authors:  Victor Ghetie; E Sally Ward
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Enhanced mucosal and systemic immune responses to intestinal reovirus infection in beta2-microglobulin-deficient mice.

Authors:  A S Major; C F Cuff
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies.

Authors:  Carlos Vaccaro; Roger Bawdon; Sylvia Wanjie; Raimund J Ober; E Sally Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

4.  Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy.

Authors:  Prashant Prabhat; Zhuo Gan; Jerry Chao; Sripad Ram; Carlos Vaccaro; Steven Gibbons; Raimund J Ober; E Sally Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-23       Impact factor: 11.205

Review 5.  Inhibitors of the FcRn:IgG protein-protein interaction.

Authors:  Susan C Low; Adam R Mezo
Journal:  AAPS J       Date:  2009-06-05       Impact factor: 4.009

6.  Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.

Authors:  Algirdas Grevys; Malin Bern; Stian Foss; Diane Bryant Bratlie; Anders Moen; Kristin Støen Gunnarsen; Audun Aase; Terje Einar Michaelsen; Inger Sandlie; Jan Terje Andersen
Journal:  J Immunol       Date:  2015-04-22       Impact factor: 5.422

Review 7.  FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin.

Authors:  Michal Pyzik; Timo Rath; Wayne I Lencer; Kristi Baker; Richard S Blumberg
Journal:  J Immunol       Date:  2015-05-15       Impact factor: 5.422

Review 8.  Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn.

Authors:  E Sally Ward; Raimund J Ober
Journal:  Adv Immunol       Date:  2009       Impact factor: 3.543

Review 9.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

10.  Impact of altered endogenous IgG on unspecific mAb clearance.

Authors:  Saskia Fuhrmann; Charlotte Kloft; Wilhelm Huisinga
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-04-24       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.